Apricus Bio Receives FDA Guidance On Phase 3 Study Design For RayVa™ Treatment For Raynaud's Syndrome, Secondary To Scleroderma
Links shared publicly online about this topic.
- 852total visits
Apricus Bio Receives FDA Guidance On Phase 3 Study Design For RayVa™ Treatment For Raynaud's Syndrome, Secondary To Scleroderma
Apricus Biosciences (Apricus Bio) (Nasdaq: APRI), backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline t
View full resource at medicalnewstoday.com
Tags: Neurovascular Disorder, Raynaud Disease, Scleroderma, Disease and Condition, Phase 3 Clinical Trial, FDA, Apri
Most Recently Shared on September 23, 2010 at 3:05 pm By:
Apricus Bio Receives FDA Guidance On Phase 3 Study Design For RayVa™ Treatment For Raynaud's Syndrome, Secondary... http://mnt.to/3Kcp
Also Shared By:
Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa" Treatment for Raynaud's Syndrome, Secondary to Scleroderma - News Press Release | PharmiWeb.com
pharmiweb.com — “Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa" Treatment for Raynaud's Syndrome, Secondary to Scleroderma - News Press Release | PharmiWeb.com” View full resource at pharmiweb.com
Most Recently Shared on September 22, 2010 at 7:56 am By:
Press Release: Apricus Biosciences (“Apricus Bioâ€) (Nasdaq: APRI), backed by a revenue-generating CRO business and... http://bit.ly/bDmAIm
Advertisement
MNT Vascular
@mnt_vascular
Apricus Bio Receives FDA Guidance On Phase 3 Study Design For RayVa™ Treatment For Raynaud's Syndrome, Secondary... http://mnt.to/3Kcp
1 year ago...